Wikipedia -WSS

Wikipedia

author：knowledge 2025-08-12 11:29:52 - browse：23279

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： A public scorecard can help hold safety

explore

WSS

Air quality improving but still lags in Black, Hispanic communities

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Custom gene therapy hints at new path for rare disease treatments

How to bring more disabled researchers into academia

Google and Epic fight stronger regulation of AI in health care

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

focus

Wikipedia

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Walensky prepares to leave CDC — and Congress — behind

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Duchenne breakthrough therapy leaves behind pioneering families

The problem with charging patients to message their doctors

Novavax promises a turnaround & Lilly roils the obesity market

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Dobbs anniversary: the lost opportunity of abortion as health care

Change Healthcare payments predicted restored March 15

focus

In early work, researchers turn to CRISPR to treat Alzheimer's

Air quality improving but still lags in Black, Hispanic communities

Medicare has a new plan to address drug shortages

The Readout: Amylyx, Alumis, and Lundbeck drug updates

How Medicaid coverage policies for immigrants impact new moms

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

focus

explore

explore

focus